This is a NIDA/SAMHSA Blending Initiative Product
The primary goal of this training package is to create awareness about buprenorphine among multi-disciplinary addiction professionals. The materials include information designed to increase motivation for bringing buprenorphine to local communities, as well as information about what to expect when someone is treated with this medication. This training is meant for clinicians. Physicians will need a different course to fulfill training requirements.
Additionally, materials discuss legislation that permits office-based buprenorphine treatment, the science of addiction, the mechanism of buprenorphine, patient selection issues, and various patient, counseling, and therapeutic issues.
Typical length of training: 4 hours
Opioid Use and Abuse
Opioid use and abuse continues to be a problem across the U.S. Research is showing the use is increasing.
- More than 3 million people over the age of 12 have used heroin at least one time.
- Between 1994 and 2001, the number of new heroin initiates was about 100,000 per year.
- Approximately 1.8% of Americans were currently using pain relievers, and approximately 2 million people had used OxyContin at least once in their lives.
The Drug Abuse Treatment Act of 2000 (DATA 2000) allows opioid treatment to continue as it has in the past, and it allows for expansion beyond the current structure to include treatment in office-based settings in addition to the traditional opioid treatment programs (OTPs). By doing so:
• More patients may be willing to seek treatment;
• More patients will have access to treatment; and
• Stigma may be reduced by broadening the definition and locations of available treatment options
Upcoming Trainings There are no Buprenorphine trainings scheduled as we are focusing on Mental Health First Aid trainings in New Mexico until the end of September.
Life Link Training Institute is proud to partner with the Southwest Node of the NIDA Clinical Trial Network, CASAA, and the Gulf Coast ATTC for the Blending Products.
